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We previously detected HIV-1 Gag-specific CD4+ T cells recognizing reference strain viral epitopes in subjects with progressive, chronic
infection. To test whether these CD4+ T cells persist in vivo by failing to recognize autologous HIV-1 epitopes, we compared autologous plasma
HIV-1 p24 nucleotide sequences with targeted HXB.2 strain Gag p24 CD4+ T cell epitopes in nine chronically infected, untreated subjects. In five
responding subjects, 10 of 26 HXB.2 strain p24 peptides targeted by CD4+ T cells exactly matched autologous plasma viral sequences. Four
subjects with plasma viral loads >100,000 copies/mL had no measurable p24-specific CD4+ T cell responses despite carrying HIV-1 strains that
matched HXB.2 sequences at predicted epitopes. These results show that HIV-1-specific CD4+ T cells can persist in chronic HIV-1 infection
despite recognition of epitopes present in vivo. However, with high-level in vivo HIV-1 replication, CD4+ T cells targeting autologous HIV-1 may
be non-responsive or absent.
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The failure of most untreated subjects to suppress human
immunodeficiency virus type 1 (HIV-1) replication during the
chronic phase of infection may result from a defect in HIV-1-
specific CD4+ T cell help. This defect may be due in part to the
selective depletion of HIV-1-specific CD4+ T cells early in the
disease course, an anticipated consequence of the preferential
infection of these cells with HIV-1 (Douek et al., 2002).
Nevertheless, HIV-1-specific, gamma interferon (IFN-γ)-pro-
ducing CD4+ T cells were found to persist in some subjects with
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doi:10.1016/j.virol.2006.10.040long-term non-progressors (Pitcher et al., 1999; Wilson et al.,
2000). Subsequently, the role of HIV-1-specific CD4+ T cell
functional abnormalities in the pathogenesis of progressive
HIV-1 disease has been investigated. Abnormalities identified
in viremic subjects to date include poor antigen-induced
proliferation under standard culture conditions (McNeil et al.,
2001; Palmer et al., 2002), as well as a proliferation-limiting
lack of IL-2 production (Boaz et al., 2002; Harari et al., 2004;
Iyasere et al., 2003; Palmer et al., 2004; Younes et al., 2003) and
an associated skewing towards expression of “effector memory”
surface markers (Harari et al., 2002; Palmer et al., 2004; Younes
et al., 2003). Diminished IL-2 production by HIV-1-specific
CD4+ T cells in subjects with chronic HIV-1 replication could
limit not just the proliferation of these cells, but also the help
they provide to HIV-1-specific cytotoxic T lymphocytes (CTL).
The defective antigen-induced proliferation of HIV-1-specific
CD8+ T cells during progressive HIV-1 disease (Lichterfeld et
al., 2004; Migueles et al., 2002) supports this possibility.
Another possible explanation for the apparent failure of HIV-
1-specific, IFN-γ-producing CD4+ Tcells to help control HIV-1
Table 1







UH156 15,379 299 ⁎0405, ⁎0701
UH168 46,704 162 ⁎0301, ⁎0401
UH178 >750,000 a 143 ⁎1101, ⁎1301
UH185 150,000 456 ⁎0901, ⁎1202
UH200 90,400 182 ⁎1302, ⁎1503
UH202 58,900 378 ⁎0701, ⁎1601
UH208 177,000 408 ⁎1101, ⁎1303
UH210 460,313 88 ⁎1101, ⁎1301
UH212 >750,000 6 ⁎0407, ⁎1601
a Value exceeded the quantitative range of the assay.
35E. Boritz et al. / Virology 361 (2007) 34–44disease progression during the chronic phase is that these cells
fail to recognize the HIV-1 epitope sequences present in vivo.
Given the high mutation rate of replicating HIV-1 (Coffin,
1992), some viral epitopes that stimulate specific CD4+ T cell
responses during early infection probably evolve to unrecogniz-
able forms under pressure from specific CTL (Barouch et al.,
2002; Birk et al., 1998; Cao et al., 2003; Goulder et al., 1997;
Jamieson et al., 2003; Kelleher et al., 2001; Leslie et al., 2004;
Soudeyns et al., 1999; Wilson et al., 1999; Yang et al., 2003),
neutralizing antibodies (Frost et al., 2005; Wang et al., 2002),
the CD4+ T cells themselves (Ciurea et al., 2001), or other
selective forces. Although inactive against autologous HIV-1
strains present during advanced infection, memory CD4+ Tcells
primed by such rapidly evolving epitopes might nevertheless
recognize reference strain HIV-1 antigens in vitro. Over time,
CD4+ T cells that do not target emerging HIV-1 variants might
persist by remaining quiescent and thus avoiding preferential
infection and depletion. In other words, among CD4+ T cells
targeting reference strain HIV-1 epitopes, the cells that do not
recognize viral epitopes present in vivo may have a survival
advantage over those that do.
Testing this hypothesis requires assays sufficiently sensitive
to detect low-frequency CD4+ T cell populations targeting
individual HIV-1 epitopes. Particularly in subjects with chronic,
progressive infection, few assays are sufficiently sensitive to
accomplish this (Scriba et al., 2005; Seth et al., 2005). To
address this difficulty, we have investigated how the defective
proliferation of HIV-1-specific CD4+ T cells from such subjects
might be improved, thus allowing in vitro expansion of these
cells for easier detection. We showed in a previous study that
depleting PBMC of CD8+ cells before antigen stimulation
allowed Gag p24 antigen-specific CD4+ T cells to proliferate in
culture (Boritz et al., 2004). These cells could then be detected
by IFN-γ production in enzyme-linked immunospot (ELISpot)
assays. Responses in the “expanded ELISpot” assay were often
detectable from subjects showing weak or absent HIV-1-
specific CD4+ T cell IFN-γ production in fresh PBMC,
demonstrating the high sensitivity of the expanded ELISpot
for low-frequency CD4+ T cell populations. Of note, subjects
with HIV-1 RNA levels >100,000 copies/mL lacked detectable
p24-specific CD4+ T cell responses even in the expanded
ELISpot, suggesting that proliferation-competent HIV-1-speci-
fic CD4+ T cells may be lost during the chronic phase of disease
only at the very highest levels of in vivo HIV-1 replication.
In the present study, we used the expanded ELISpot
technique to detect HXB.2 strain p24 peptide-specific CD4+
T cell responses for comparison with autologous plasma HIV-1
p24 amino acid sequences. We aimed to test the hypothesis that
HIV-1 antigen-specific, IFN-γ-producing CD4+ T cells detected
during progressive HIV-1 disease persist despite chronic HIV-1
replication by failing to recognize the HIV-1 epitopes present in
vivo, thus avoiding preferential infection and deletion. If this
hypothesis were correct, we expected to observe significant
amino acid sequence differences between HXB.2 strain CD4+ T
cell target peptides and corresponding autologous HIV-1
sequences. Instead, several subjects had CD4+ T cells
recognizing p24 amino acid sequences present in autologousvirus, and we found little evidence that these CD4+ T cells had
selected for escape mutations within their target sequences.
Furthermore, because plasma HIV-1 molecular clones from
several subjects with the highest HIV-1 loads encoded p24
sequences predicted to be CD4+ T cell targets, we could not
attribute the lack of p24-specific CD4+ T cell responses in these
subjects to sequence differences between the reference HXB.2
strain and autologous virus.
Results
Study subjects
Nine antiretroviral therapy-naïve adults with chronic HIV-1
infection, based on history and physical exam, HIV-1 ELISA,
and fully evolved Western blot, were recruited for this study.
Table 1 shows that all of these subjects had significant viremia
at the time of study, with plasma HIV-1 RNA loads ranging
from 15,379 to greater than 750,000 copies/mL (median
150,000 copies/mL). Their peripheral blood CD4+ T cell counts
ranged from 6 to 456 cells/μL (median 182 cells/μL), and 5 of 9
met criteria for AIDS with CD4 counts below 200 cells/μL. As
no subject was suspected to have been infected during the
6 months leading up to study, these low CD4 counts (normal
range 500–1600 cells/μL) were taken as signs of chronic,
progressive HIV-1 infection. Finally, as major histocompat-
ibility complex (MHC) class II molecules restrict epitope
presentation to CD4+ T cells and thus help determine which
epitopes may become CD4+ T cell targets, we determined the
HLA–DRB1 alleles expressed by each subject. As expected, a
variety of different alleles were expressed among the 9 subjects,
although 4 subjects shared expression of HLA–DRB1∗13
alleles (see Table 1). Of note, although DRB1∗13 alleles have
been associated with non-progressive HIV-1 infection, the four
subjects in this study bearing these alleles had among the
highest plasma viral loads in the group (Malhotra et al., 2001).
HIV-1 p24 peptide-specific CD4+ T cell responses
As shown in Table 2, CD4+ T cell epitope recognition
patterns were variable among the 9 study subjects. Four subjects
had CD4+ T cells recognizing multiple p24 epitopes, ranging
from 4 peptides targeted in UH168 to 10 in UH200. Of note,
Table 2
HIV-1 p24 peptide-specific CD4+ T cell responses of treatment-naive study subjects determined in expanded IFN-γ ELISpot assays
p24 peptide a CD4+ T cell response (Net IFN-γ SFCs/106 CD3+CD4+ lymphocytes) b
UH156 UH168 UH178 UH185 UH200 UH202 UH208 UH210 UH212
Pool 1778 823 – 3448 8704 NAc – – –
131–150 – – – – 2593 383 – – –
141–160 – – – – – – – – –
151–170 333 – – – 1481 1571 – – –
161–180 – – – – – 421 – – –
171–190 – – – – 1296 – – – –
181–195 – – – – 3519 – – – –
185–199 – – – – – – – – –
189–203 – – – – – – – – –
191–210 – – – – 1111 – – – –
201–220 556 – – – 926 – – – –
211–230 611 412 – 1778 – 613 – – –
221–240 – 494 – – – – – – –
231–250 389 2963 – – 1111 – – – –
241–260 – – – – – – – – –
251–270 – – – – 1667 – – – –
261–280 – – – – 6296 – – – –
271–290 – – – – – 1264 – –
281–300 – – – – – – – – –
291–310 500 412 – – 3981 1609 – – –
301–320 – – – – – – – – –
311–330 – – – – – – – – –
321–340 – – – – – – – – –
331–350 – – – – – – – – –
341–360 – – – – – – – – –
349–363 – – – – – – – – –
# Targets d 5 (4) 4 (3) 0 1 10 (7) 6 (5) 0 0 0
a HIV-1 Gag p24 peptides designated by amino acid residue positions within the HXB.2 strain sequence of Gag. “Pool,” results from stimulation with a pool of all 25
peptides shown.
b The median net response to the pool of p24 peptides among the 10 negative control subjects was 16 SFCs/106 CD3+CD4+ lymphocytes, or less than 1 SFC/well.
Net responses of 4 SFCs/well greater than this negative control value were considered positive. Negative responses are shown as dashes.
c NA, not attempted.
d Number of individual peptides stimulating positive responses. Numbers in parentheses represent minimum number of positive epitope-specific responses if
contiguous positive peptides are assumed to represent a single epitope-specific response.
Fig. 1. Significant inverse correlation of plasma HIV-1 RNA level with number
of p24-specific CD4+ T cell target peptides, as shown for each study subject in
Table 2. Spearman's R and p values are shown.
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thus met CD4 cell count criteria for AIDS. By contrast, UH185
responded to a only single peptide, and 4 subjects (UH178,
UH208, UH210, and UH212) showed no p24 peptide-specific
CD4+ T cell responses at all. The level of HIV-1 replication in
vivo predicted the breadth of p24-specific CD4+ T cell
responses, as plasma HIV-1 RNA levels were inversely
correlated with the number of p24 peptides targeted (Fig. 1).
This association remained significant using “minimum” breadth
estimates in which paired responses to adjacent p24 peptides
overlapping by 10 residues were assumed to represent a single
epitope-specific response (Spearman's R=−0.804, p=0.014).
No significant association was found between maximum
breadth of epitope recognition and peripheral CD4 T cell
count (Spearman's R=0.38, p=0.3).
RT–PCR and sequencing of plasma HIV-1 p24 genes
Fig. 2 is a neighbor-joining phylogenetic tree demonstrating
the relationships among all 63 p24 nucleotide sequences from
the study subjects. It shows that 59 of 63 sequences were
unique. All sequences were different from the HXB.2 referencestrain upon which synthetic peptides were based, with genetic
distances ranging from approximately 2.5% nucleotide
sequence non-identity in UH208 to over 10% non-identity in
UH156 (a subject who contracted HIV-1 in Ethiopia). Finally,
p24 nucleotide sequences from each subject were more closely
related to one another than to any of the other sequences. This
confirmed that samples had not been contaminated with
Fig. 2. Neighbor-joining phylogenetic tree showing clustering of plasma HIV-1
Gag p24 molecular clones at the nucleotide level. Each terminal branch repre-
sents a single molecular clone; clusters of clones from each subject are labeled
with subject numbers. Numbers at nodes indicate percentages of 1000 bootstrap
resamplings in which given clusters were supported. Distances between clones
are determined by summation of intervening horizontal branch lengths. The
scale bar represents a distance of 1.0% nucleotide non-identity between
sequences. HXB.2 is the clade B reference strain upon which synthetic peptides
were based. The sequence of AY334290, an HIV-1 clade A isolate derived in
Ethiopia, was obtained from the Los Alamos HIV Sequence Database and
included to show proximity to the sequences from UH156, who was infected
with HIV-1 in Ethiopia.
37E. Boritz et al. / Virology 361 (2007) 34–44extraneous nucleic acid before or during RT–PCR. Alignments
of amino acid sequences deduced from the p24 molecular
clones of individual study subjects are provided in the
Supplementary data.
Autologous plasma HIV-1 p24 amino acid sequences
corresponding to HXB.2-derived CD4+ T cell target peptides
Table 3 shows the deduced autologous HIV-1 amino acid
sequence data at all HXB.2-based target peptides identified
from the 5 subjects with detectable p24-specific CD4+ T cell
responses. It shows that all 5 subjects had CD4+ T cells
targeting HXB.2 strain peptides that differed from correspond-
ing autologous p24 amino acid sequences. Targeted HXB.2
strain p24 sequences differed from autologous sequences at up
to 3 positions in some cases (the 151–170 peptide in UH156,
and the 211–230 peptide in UH202). On the other hand, several
subjects showed CD4+ T cell recognition of HXB.2 peptides
that exactly matched autologous viral clones. For example, 7 of
10 HXB.2 target peptides from UH200 and 1 of 6 from UH202were identical to HXB.2 in all autologous clones. In UH168,
although no HXB.2 target epitope exactly matched every
autologous clone, 2 of 4 matched at least 50% of the clones
sequenced. Altogether, of 26 HXB.2 strain peptides found to
contain CD4+ T cell epitopes, 10 exactly matched some or all
corresponding autologous viral sequences from the subjects
with responses against them. Furthermore, many amino acid
differences between HXB.2 strain target peptides and auto-
logous epitopes were highly conservative. Examples are V215L
in UH156, UH168, UH185, and UH200; E203D in UH156; and
S310T in UH156, UH168, and UH202.
Non-synonymous genetic variation with p24-specific CD4+ T
cell target regions
To determine whether the p24 epitope-specific CD4+ T cells
might select for escape mutations at their target epitopes, we
examined whether the ratio of non-synonymous to synonymous
nucleotide substitutions (dN/dS) was greater within CD4+ T cell
target epitopes than in untargeted regions of p24. Table 4 shows
that of 9 subjects studied, only UH212 had a group of plasma
p24 clones with no non-synonymous variation among them
(i.e., all amino acid sequences were identical). At least 2
different deduced p24 amino acid sequences were detected from
the plasma of the remaining 8 subjects. In the groups of isolates
from 5 subjects with p24 peptide-specific CD4+ T cell
responses, dN/dS was greater inside than outside CD4+ T cell
target regions only among the isolates from UH168 (Table 4).
By contrast, isolates from UH156, UH185, UH200, and UH202
showed no increased dN/dS inside CD4+ T cell target regions,
with dN/dS of zero in the CD4+ T cell target regions of UH185
and UH200.
Differences between HXB.2 strain and autologous HIV-1 p24
amino acid sequences in subjects with HIV-1 RNA levels
>100,000 copies/mL
We asked whether the subjects with the highest viral loads
might be infected with HIV-1 strains that differed widely from
the HXB.2 strain, and might thus appear to lack p24-specific
CD4+ T cell responses because autologous virus-specific
responses could not cross-recognize HXB.2 peptides. Accord-
ingly, the median p24 amino acid sequence non-identity
between HXB.2 and the plasma p24 clones from each subject
was calculated. Table 5 shows that differences between
autologous and HXB.2 p24 sequences ranged from 0.9% (in
UH210) to 10.2% (in UH156). Percentage difference from
HXB.2 was not significantly greater in the 4 subjects lacking
p24-specific CD4+ T cell reactivity than in the 5 responders
(p=0.556, Mann–Whitney), and greater percentage difference
from HXB.2 did not predict either weaker or more narrowly
directed CD4+ T cell reactivity (Spearman's R=0.3805,
p= 0.360, magnitude; Spearman's R= 0.174, p= 0.634,
breadth). Therefore, differences between autologous and
HXB.2 p24 amino acid sequences did not appear to explain
the limited p24-specific CD4+ T cell reactivity in subjects with
viral loads >100,000 copies/mL.
Table 3
Autologous plasma HIV-1 p24 amino acid sequences corresponding to HXB.2 strain CD4+ T cell target peptides
Subject Targeted HXB.2 peptides Autologous plasma
HIV-1
Position Sequence Variant sequences a % HXB.2 b
UH156 151–170 TLNAWVKVVEEKAFSPEVIP V159I, V168I, P170S (1/6) 0
201–220 LKETINEEAAEWDRVHPVHA E203D, V215L 0
211–230 EWDRVHPVHAGPIAPGQMRE V215L, I223V 0
231–250 PRGSDIAGTTSTLQEQIGWM G248A 0
291–310 EPFRDYVDRFYKTLRAEQAS Y301F, S310T 0
UH168 211–230 EWDRVHPVHAGPIAPGQMRE V215L, I223V (3/6) 0
221–240 GPIAPGQMREPRGSDIAGTT I223V (3/6) 50
231–250 PRGSDIAGTTSTLQEQIGWM I247V, G248R (1/6) 0
291–310 EPFRDYVDRFYKTLRAEQAS D295G (1/6), S310T (1/6) 67
UH185 211–230 EWDRVHPVHAGPIAPGQMRE V215L 0
UH200 131–150 NYPIVQNIQGQMVHQAISPR I138M 0
151–170 TLNAWVKVVEEKAFSPEVIP None 100
171–190 MFSALSEGATPQDLNTMLNT None 100
181–195 PQDLNTMLNTVGGHQ None 100
191–210 PQDLNTMLNTVGGHQ None 100
201–220 LKETINEEAAEWDRVHPVHA V215L 0
231–250 PRGSDIAGTTSTLQEQIGWM None 100
251–270 TNNPPIPVGEIYKRWIILGL None 100
261–280 IYKRWIILGLNKIVRMYSPT None 100
291–310 EPFRDYVDRFYKTLRAEQAS T303V 0
UH202 131–150 NYPIVQNIQGQMVHQAISPR I138L (6/8), I147L 0
151–170 TLNAWVKVVEEKAFSPEVIP V159I 0
161–180 EKAFSPEVIPMFSALSEGAT None 100
211–230 EWDRVHPVHAGPIAPGQMRE V215M, H219Q, M228I 0
271–290 NKIVRMYSPTSILDIRQGPK T280V 0
291–310 EPFRDYVDRFYKTLRAEQAS S310T 0
a First letters refer to the HXB.2 sequence, numbers refer to residue positions, and second letters refer to the subjects' autologous variants. The proportion of the
molecular clones in which each variant occurred is shown in parentheses; variants with no proportions specified occurred in all molecular clones.
b Percentage of the molecular clones from each subject encoding amino acid sequences identical to the HXB.2 sequence at these positions.
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HXB.2 strain p24 peptide-specific CD4+ T cell responses were
infected with HIV-1 strains that differed from HXB.2 by only a
few critical amino acid residues. To test this, we searched the
HIV Molecular Immunology Database for epitopes predicted toTable 4
Variation of plasma HIV-1 p24 amino acid sequences inside and outside of CD4+
T cell target regions
Subject CD4+ T cell target regions a Untargeted regions
Proportion







UH156 1/90 (1.1%) 0.065 4/141 (2.8%) 0.097
UH168 4/60 (6.7%) 0.147 2/171 (1.2%) 0.096
UH178 – – 6/231 (2.6%) 0.135
UH185 0/20 (0.0%) 0.000 5/211 (2.4%) 0.063
UH200 0/158 (0.0%) 0.000 2/73 (2.7%) 0.073
UH202 1/108 (0.9%) 0.183 1/123 (0.8%) 0.279
UH208 – – 3/231 (1.3%) 0.107
UH210 – – 2/231 (0.9%) 0.033
UH212 – – 0/231 (0.0%) 0.000
a Residue positions spanned by peptides that stimulated CD4+ Tcell responses
in expansion IFN-γ ELISpot assays.
b Proportion of residue positions within given region occupied by 2 or more
different amino acids (aa) among subject's group of p24 sequences.
c Corrected ratio of non-synonymous to synonymous nucleotide variations
among sequences coding for given region. Determined according to the method
of Nei and Gojobori as described in Materials and methods.be presented by the MHC class II molecules expressed by these
subjects. Subjects UH178 and UH210 both expressed HLA–
DRβ1∗1301, which has previously been shown in natural
infection to restrict CD4+ T cell recognition of epitopes within
HXB.2 strain peptides 251–265, 260–269, and 265–282
(Malhotra et al., 2001; Kaufmann et al., 2004). CD4+ T cell
recognition of peptides overlapping these epitopes was detectedTable 5
Percentage sequence difference between autologous plasma HIV-1 p24 clones
and the HXB.2 sequence, and relationship to magnitude and breadth of HXB.2
strain p24-specific CD4+ T cell reactivity
Subject Median difference
from HXB.2 a
p24-specific CD4+ T cell responses
Magnitude # Targets
UH156 23.5 (10.2%) 1778 5 (4)
UH168 8 (3.5%) 823 4 (3)
UH178 7.5 (3.2%) – 0
UH185 3 (1.3%) 3448 1
UH200 5.5 (2.4%) 8704 10 (7)
UH202 10 (4.3%) NAb 6 (5)
UH208 5 (2.2%) – 0
UH210 2 (0.9%) – 0
UH212 12 (5.2%) – 0
a Number (percentage) of 231 amino acid residues not identical to the
equivalent positions in the HXB.2 strain sequence of Gag p24. Value shown is
the median from the 5–10 molecular clones from each subject's plasma.
b NA, not attempted.
Table 6
Differences between autologous and HXB.2 reference strain p24 amino acid sequences in HLA–DRβ1∗1301-expressing subjects lacking p24-specific CD4+ T cell
reactivity
Subject Predicted HLA–DRβ1*1301-restricted epitopes a Other non-HXB.2 positions c
Position Sequence Autologous variants Autologous % HXB.2 b
UH178 251–265 TNNPPIPVGEIYKRW N252S (6/8), I256T (7/8) 12.5 I138L, V215L, E312D, A340G, G357S
260–269 EIYKRWIILG None 100
265–282 WIILGLNKIVRMYSPTSI None 100
UH210 251–265 TNNPPIPVGEIYKRW None 100 I138L
260–269 EIYKRWIILG None 100
265–282 WIILGLNKIVRMYSPTSI None 100
a HXB.2 strain epitopes that bound tightly to HLA–DRβ1∗13 molecules and were targeted by CD4+ T cells from HIV-1-infected subjects expressing these HLA
molecules in previous studies [251–265 and 260–269 (Malhotra et al., 2001); 265–282 (Kaufmann et al., 2004)].
b Percentage of the molecular clones from the given subject encoding amino acid sequences identical to the HXB.2 sequence at these positions.
c HIV-1 Gag p24 residue positions outside predicted HLA–DRβ1∗1301-restricted epitopes at which all autologous p24 molecular clones sequenced differed from
the HXB.2 strain sequence. First letters refer to the HXB.2 sequence, numbers refer to Gag residue position numbers, and second letters refer to the subjects'
autologous sequences.
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who expressed HLA–DRβ1∗1302 (see Tables 2 and 3). By
contrast, neither UH178 nor UH210 showed CD4+ T cell
recognition of these epitopes even though at least 1 autologous
p24 molecular clone sequenced from each subject exactly
matched the corresponding HXB.2 sequence at each epitope
(Table 4). Outside the predicted epitopes, autologous p24
sequences from subject UH210 consistently differed from the
HXB.2 sequence only by a single leucine for isoleucine
substitution; sequences from UH178 consistently differed by
the HXB.2 sequence by 5 largely conservative substitutions
(Table 6).
Discussion
A key finding of this study is that peripheral blood CD4+ T
cells from several treatment-naive subjects with advanced HIV-1
infection targeted reference HXB.2 strain amino acid sequences
also present in autologous plasma HIV-1. In previous studies,
CD4+ T cell recognition of autologous HIV-1 epitopes was
observed during early infection. Two groups have reported on
individual CD4+ T cell clones targeting autologous Env or Gag
epitopes from subjects starting antiretroviral therapy during acute
disease (Malhotra et al., 2003; Norris et al., 2004). Harcourt et al.
found Gag-specific CD4+ T cells targeting provirus-encoded
epitopes from two subjects with normal CD4 counts (Harcourt et
al., 1998). Finally, a study from our group demonstrated CD4+ T
cell targeting of autologous plasma HIV-1 Gag sequences in
subjects with CD4 counts as low as 430 cells/μL (Koeppe et al.,
2006). In subjects with later stage infection, however, reference
strain HIV-1 epitopes targeted by CD4+ T cells have not
previously been compared against autologous HIV-1 amino acid
sequences. The present study included a majority of subjects
meeting CD4 count criteria for AIDS, 2 of whom had multiple
CD4+ T cell responses against Gag p24 epitopes that matched the
corresponding epitopes from autologous virus.
An important interpretation of this finding is that the CD4+ T
cell responses from these subjects targeting reference strain
HIV-1 antigens were not simply residual responses against
epitopes no longer present in vivo. Because HIV-1 protein-coding sequences during chronic, progressive infection may
rapidly diverge from those of the original transmitted strain
(Delwart et al., 1997; Liu et al., 1997; Shankarappa et al., 1999),
CD4+ T cells primed by early strains may not recognize
emerging variants during the chronic phase. Given the
preferential infection of HIV-1-specific CD4+ T cells with
HIV-1, continued recognition of emerging variants may cause
HIV-1-specific CD4+ T cells to be deleted in vivo. We had
therefore hypothesized that CD4+ T cell responses against
reference strain HIV-1 antigens during advanced disease might
represent those HIV-1-specific CD4+ T cells originally primed
by epitopes that had rapidly mutated early in the disease course.
Our results are not consistent with this hypothesis, and instead
suggest that the failure of HIV-1-specific CD4+ T cells detected
during chronic infection to mediate HIV-1-specific immune
protection does not result entirely from an inability to recognize
autologous viral epitopes. Instead, as the CD4+ T cell responses
in this study were detected only after in vitro expansion using
optimized culture conditions, defects in their magnitude or
effector functions may have limited their in vivo protective
effects.
The mechanisms by which specific CD4+ T cell responses
against actively replicating HIV-1 strains might persist into
advancedHIV-1 disease are unclear. It is possible that someCD4+
Tcells recognizing autologous viral epitopes in vitro nevertheless
fail to respond to these sequences in vivo. In particular, the use of
costimulatory molecules and high peptide concentrations in the
ELISpot assay may allow in vitro activation of HIV-specific
CD4+ T cells with insufficient functional avidity to react against
APCs presenting autologous HIV-1 antigens in vivo. However, it
is also possible that some HIV-1-specific CD4+ Tcells respond to
antigen in vivo without being infected. HIV-1-specific CD4+ T
cells might resist HIV-1 infection in vivo by expressing
insufficient levels of chemokine receptors or other genes required
for HIV-1 entry, reverse transcription, or integration. Alterna-
tively, these cells might express coreceptor-blocking chemokines,
as has been observed previously (Abdelwahab et al., 2003; Saha et
al., 1998). Finally, it remains possible that the HIV-1-specific
CD4+ T cells we detected in this study were infected with HIV-1,
and that they persist in vivo at the cost of continuous, rapid
40 E. Boritz et al. / Virology 361 (2007) 34–44turnover. Further investigation will be required to determine the
exact mechanisms bywhich CD4+ Tcells recognizing autologous
HIV-1 antigens persist in vivo during chronic HIV-1 infection.
It was interesting thatmanyCD4+ Tcell responses in this study
recognizedHXB.2 strain p24 amino acid sequences differing by 1
or more residues from corresponding autologous sequences.
Although this study was limited by not directly testing CD4+ T
cell responses to autologous epitope peptides, we speculate that
some of these responses could still have represented CD4+ Tcells
capable of targeting the viral epitopes present in vivo. Because
target epitopes were mapped using 20-residue peptides, it is
possible that differences between these peptides and autologous
sequences fell outside the regions required for CD4+ T cell
recognition. Furthermore, because of the promiscuity of MHC
class II-peptide binding (Southwood et al., 1998), the conserva-
tive sequence differences we observed might not disrupt CD4+ T
cell recognition even if these differences occurred at critical
positions. Nevertheless, it remains possible that some of the
HXB.2 strain-specific CD4+ T cell responses in this study would
not have cross-recognized the autologous variant epitopes we
detected, but instead reflected priming by autologous variants no
longer present in vivo. Analysis of earlier plasma samples, or of
“archived” proviral sequences in PBMC DNA, might have
revealed such variants. Further studies will be required to address
this possibility.
The non-synonymous mutation rates inside CD4+ Tcell target
regions were lower than the rates outside these regions among
autologous sequences from 4 of 5 subjects, and thus failed to
support direct CD4+ T cell-mediated selective pressure on target
epitopes in vivo. This could mean that HIV-1-specific CD4+ T
cells do not select for mutations at their target epitopes during
chronic, progressive HIV-1 infection. As discussed above, it is
possible that the cells detected in this study had insufficient
functional avidity to respond to their target epitopes in vivo. It is
also possible that the cells we detected had no direct antiviral
effector activity even after activation in vivo, and thus contributed
to selective pressure only at epitopes targeted by specific B cells
and CTL receiving their “help.” On the other hand, we may have
failed to detect HIV-1-specific CD4+ T cell-mediated selective
pressure due largely to the limitations of our experimental design.
The use of reference strain HIV-1 Gag peptides to detect T cell
responses may have biased toward recognition of conserved
epitopes. Also, cross-sectional dN/dS analysis detects genomic
areas inwhich amino acid variation benefits the virus at the time of
analysis, but does not detect areas where immune escape has
already become fixed. Furthermore, mutations within the p24
antigen may be particularly deleterious to the virus, as has been
observed in a study of p24-specific CD8+ T cell-mediated
selection (Martinez-Picado et al., 2006). Therefore, non-synon-
ymous genetic variation is probably more prevalent elsewhere in
the genome. Longitudinal studies of CD4+ T cell responses
against regions that better tolerate mutation will aid in under-
standing how mutational escape from these responses might
influence HIV-1 pathogenesis.
Finally, we examined whether subjects with plasma HIV-1
RNA levels >100,000 copies/mL harbored a predominance of
HIV-1 strains with p24 amino acid sequences differing widelyfrom the HXB.2 sequence. We hypothesized that the inverse
association we and others have documented between such high
viral loads and HIV-1-specific CD4+ T cell IFN-γ production in
vitro (Boritz et al., 2004; Oxenius et al., 2002) might reflect an
inability of CD4+ T cells targeting autologous viral epitopes in
highly viremic subjects to cross-recognize corresponding HXB.2
epitopes. Although we did not test recognition of autologous
variant epitopes in this study, our results do not favor this
explanation. Most amino acid sequence differences between
HXB.2 and autologous sequences in subjects with the highest
viral loads were conservative, and in subject UH210, there was
only a single position within the p24 sequence at which all
autologous clones sequenced differed from HXB.2. Furthermore,
at the three HXB.2 epitope positions predicted to be HLA–
DRβ1∗1301-restricted CD4+ Tcell targets (Malhotra et al., 2001;
Kaufmann et al., 2004), the HXB.2 sequence exactly matched at
least one autologous sequence from both highly viremic,
DRβ1∗1301-expressing subjects. We therefore speculate that
the most highly viremic subjects lacked functional HIV-1-specific
CD4+ T cell responses even against autologous p24 epitopes,
perhaps reflecting ablation of virus-specific Tcells by persistently
high viremia (Fuller and Zajac, 2003), T cell receptor antagonism
of these cells by low frequency epitope variants in vivo (Frasca et
al., 1999; McElrath and Kent, 1997), or other mechanisms.
Nevertheless, we cannot exclude the possibility that CD4+ Tcells
targeting the few autologous viral variant sequences were present
in these highly viremic subjects. Further studies addressing this
possibility will have to test the variant-specific responses of these
subjects, as has been done using HIV-1-specific CD8+ T cell
epitopes (Altfeld et al., 2003).
Overall, our results emphasize the potential of the peripheral
CD4+ T cell pool to target multiple HIV-1 epitopes even during
advanced HIV-1 disease, and establish for the first time that the
reference HXB.2 strain may accurately represent some CD4+ T
cell target epitopes present in later disease stages. This raises the
possibility that HIV-1-specific CD4+ T cells recognizing auto-
logous viral sequences in vitro might resist preferential depletion
by HIV-1 in vivo, either by remaining quiescent or by failing to
support productive infection despite antigenic stimulation.
However, subjects with the highest levels of in vivo HIV-1
replication often lack measurable CD4+ T cell responses against
the HXB.2 strain even though HXB.2 sequences accurately
represent important autologous p24 epitopes. It will be important
to determine whether such subjects lose HIV-1-specific CD4+ T
cell responses during their disease course, or whether they fail to
raise such responses from the outset of infection. In the latter case,
therapeutic immunization and other immune-based strategiesmay
help generate CD4+ T cell memory against predicted epitopes,




HIV-1-infected subjects were recruited from the Adult
Infectious Diseases Group Practice at the University of Colorado
41E. Boritz et al. / Virology 361 (2007) 34–44Hospital. Nine subjects who had never received antiretroviral
drugs previously (i.e., were “treatment-naïve”) but who met
clinical criteria for treatment initiation (recorded CD4 count
value <350 cells/μL or plasma HIV-1 RNA >100,000 copies/
mL) were selected for this study. Subjects with suspected acute
or recent infection were excluded. All subjects gave informed
consent to participate in this study, and the study was approved
by the University of Colorado Health Sciences Center Institu-
tional Review Board.
Human leukocyte antigen (HLA) typing
Molecular HLA typing was carried out by the University of
Colorado Health Sciences Center Histocompatibility Labora-
tory. High-resolution HLA–DRB1 typing was performed using
the sequence-based typing method with commercial kits from
Perkin-Elmer (Boston, MA).
Cell culture
The standard culture medium for cell expansion cultures and
IFN-γ ELISpot assays was RPMI 1640 (Invitrogen, Carlsbad,
CA)+10% heat-inactivated human AB serum (Gemini Bio-
Products, Woodland, CA)+1× penicillin/streptomycin/gluta-
mine (Invitrogen). All cultures were incubated at 37 °C in a 5%
CO2 humidified atmosphere.
Expanded IFN-γ ELISpot assays
HIV-1 p24-specific, IFN-γ-producing CD4+ T cells were
expanded from peripheral blood and detected as previously
described (Boritz et al., 2004). Peripheral blood mononuclear
cells (PBMC) were harvested by density gradient centrifugation
and depleted of CD8+ cells using CD8 microbeads (Miltenyi
Biotec, Auburn, CA). CD8-depleted PBMC (1–3×107) were
then suspended at 5×106 cells/mL in standard culture medium
and stimulated with 5 μg/mL recombinant HIV-1 Gag p24
antigen (Protein Sciences, Meriden, CT) in 6-well, polystyrene
plates. Cells were fed with 0.5× volume (1–3 mL) of standard
culture medium after 2 days of incubation. After 7 days, cells
were gently scraped from wells, depleted again of residual
CD8+ cells using CD8 microbeads, and resuspended in standard
culture medium. Cells were then plated at 4.5×104/well in 96-
well, nitrocellulose-backed plates (Millipore, Bedford, MA)
that had been coated with anti-IFN-γ monoclonal antibody (1-
D1K, mouse IgG1; Mabtech, Nacka, Sweden), washed 3×, and
blocked with standard culture medium. Stimuli used in these
assays included pooled, 20- and 15-amino acid p24 peptides
overlapping one another by 10 or 11 amino acids and spanning
residues 131–363 of the HXB.2 strain of HIV-1 Gag (1 μg/mL
each peptide; provided by the NIH AIDS Research and
Reference Reagent Program, Rockville, MD); individual p24
peptides from the pool at 5 μg/L each; 1 μg/mL phytohemag-
glutinin (PHA; Murex Diagnostics, Dartford, UK) as a positive
control; and dimethyl sulfoxide (DMSO) at 0.2% (v/v) as a
control for the solvent used in the peptide preparations.
Monoclonal CD28 antibody (eBiosciences, San Diego, CA)was included at a final concentration of 1 μg/mL. Plates were
then incubated and developed as previously described, and
spots were counted using a dissecting microscope (Boritz et al.,
2004). The net p24 peptide-specific, IFN-γ spot-forming cells
(SFCs) per million CD4+ T cells was calculated by normalizing
the number of peptide-induced SFCs/well to the CD3+CD4+
lymphocyte count measured by flow cytometry in a parallel
expansion culture. The formula used for this calculation was as
follows: (median p24-induced spot forming cells (SFCs)/well
−median medium-induced SFCs/well) × (106/4.5×104)× (1/
proportion viable cells with CD3+CD4+ lymphocyte pheno-
type). Net p24 peptide-induced responses of 4 SFCs/well
greater than the median net p24 peptide pool-induced response
from the negative control group were considered positive.
Amplification of HIV-1 nucleotide sequences by reverse
transcription PCR (RT–PCR)
Plasma from HIV-1-infected subjects was obtained at the
time of expansion IFN-γ ELISpot assays by centrifugation of
EDTA-treated blood. Plasma was then stored frozen at
−20 °C. After thawing, HIV-1 RNA was extracted using the
QiaAmp Viral RNA Isolation Kit (Qiagen Inc., Valencia, CA)
and dissolved in RNAse-free H2O. Viral p24 cDNA was
prepared using Omniscript reverse transcriptase (Qiagen) and
the p24 outside reverse 2 primer (5′-ATC TTC CCT AAA
AAA TTA GCC TGT C-3′; all primers synthesized by
Integrated DNA Technologies, Inc., Coralville, IA). Viral
cDNA was then amplified using the Expand High Fidelity
PCR System (Roche Diagnostics GmbH, Penzberg, Germany)
according to manufacturer's instructions. To avoid founder
effects resulting from chance amplification of different cDNA
quasi-species in the PCR, each subject's cDNA was amplified
in four separate sets of reactions, and the products were
pooled after the second PCR step. The first reaction used the
primers p24 outside forward (5′-AGT ATG GGC AAG CAG
GGA GC-3′) and p24 outside reverse 2; the second reaction
used the primers p24 inside forward 1 (5′-AGA GAT AAA
AGA CAC CCA GGA AGC-3′) and p24 inside reverse (5′-
TTC CAC ATT TCC AAC AGC CC-3′). The second reaction
produced a fragment including the entire p24 capsid sequence
and a small amount of upstream flanking matrix and
downstream flanking nucleocapsid sequences from the gag
polyprotein gene. PCR products were then ligated into the
pCR 2.1-TOPO vector using the TOPO TA Cloning kit
(Invitrogen) and transformed into chemically competent One
Shot E. coli. Transformants were selected on LB-Ampicillin
plates and plasmid DNA was prepared using the QiaPrep Spin
Miniprep Kit (Qiagen).
Nucleotide and amino acid sequence analysis
The nucleotide sequences of individual molecular clones
were determined in both sense and antisense directions with
ABI Prism kits (Applied Biosystems, Foster City, CA)
containing AmpliTaq DNA Polymerase. The reaction products
were run on an ABI Prism 3730 DNA fluorescent capillary
42 E. Boritz et al. / Virology 361 (2007) 34–44automated sequencer. Sequences were analyzed with Sequen-
cing Analysis version 3.3 (Applied Biosystems); sense and
antisense sequences from each clone were aligned with
Sequencher 3.1 (Gene Codes Corporation, Ann Arbor, MI)
and agreement of the two sequences through the gag p24
coding region was verified. An unreadable pair of sequences
from a single molecular clone in subject UH212 was
discarded. Phylogenetic sequence analysis was performed by
the neighbor-joining method and subjected to 1000 bootstrap
replicates using the PHYLIP v3.65 software package
(Felsenstein, 1989). Adjusted ratios of non-synonymous to
synonymous mutational frequencies (dN/dS) among molecular
p24 clones from individual study subjects were calculated
according to the method of Nei and Gojobori (Nei and
Gojobori, 1986) using the Synonymous Nonsynonymous
Analysis Program (Korber, 2001) on the HIV Sequence
Database (http://hiv-web.lanl.gov/content/hiv-db/mainpage.
html).
HIV-1 p24 epitopes predicted to be CD4+ T cell targets in
subjects lacking in vitro HIV-1-specific CD4+ T cell responses
were sought using the HIV Molecular Immunology Database at
http://hiv-web.lanl.gov/content/immunology/helper_search. A
search was performed in 04/06 using the following search
terms: protein=“p24,” subtype=“all,” immunogen=“HIV-1
infection,” and species=“human.” Each epitope from this
search was used for further analysis under the following
conditions: (1) the epitope was predicted by a previous study to
bind an HLA molecule expressed by one or more of the above
subjects, and (2) this HLA molecule was found to restrict CD4+
T cell recognition of the epitope by memory CD4+ T cells from
other HIV-1-infected subjects in a previous study.
All nucleotide sequences obtained in this study were
submitted to GenBank (http://www.ncbi.nlm.nih.gov). Acces-
sion numbers are DQ493657–DQ493719.
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